GSK-linked investigators deported from China; Aussies backed off statins after critical TV report;

@FiercePharma: Why The Trans Fat Ban and Labels On Salt And Soda Won't Make Us Healthier. More from Forbes | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales. Article | Follow @CarlyHFierce

> The private investigators linked to GlaxoSmithKline's ($GSK) bribery scandal in China have been deported from that country after being released early from prison. Report

> More than 60,000 Australians backed away from using statin drugs after a 2013 Catalyst TV program criticized the meds, raising the risk of heart attacks and strokes in that group, a new study found. Report

> Germany has the best record in Europe of getting new meds to patients "quickly and comprehensively," a report from EurActiv Germany states; pharma trade groups questioned the study, however. Report

> The CVS Health ($CVS) buyout of Target's ($TGT) pharmacy operations could spur supermarkets to seek out professional pharmacy partners. Report

> PhRMA elected 5 new members to its board of directors, including Bayer HealthCare Chairman Werner Baumann and new Bristol-Myers Squibb ($BMY) CEO Giovanni Caforio. Release

> Johnson & Johnson's ($JNJ) vision unit Vistakon is plowing €100 million into a new manufacturing facility in Limerick, Ireland, with plans to create 200 new jobs. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Sweden's Elekta hits Varian Medical with patent suit over cancer care devices. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Alcon gets CE mark to sell new intraocular lens in Europe. Report | Follow @VarunSaxena2

@EmilyWFierce: "You're a regulator. Regulate." NYT story | Follow @EmilyWFierce

> HeartWare, hit with its fifth Class 1 recall of 2015, will replace defective blood pump controllers. Story

> Irish startup Neuravi raises $21M to get stroke stent retrieval device through pivotal trial. News

Biotech News

@FierceBiotech: With IPO in mind, cancer player CytomX steps up with a $70M round. News | Follow @FierceBiotech

@JohnCFierce: Deputy at China agency that probed GSK arrested for corruption, report says. FiercePharmaAsia article | Follow @JohnCFierce

@DamianFierce: And hey $AGN's spending $2.1B on $KYTH and its chin-fat-reducing injection. Release | Follow @DamianFierce

> GlaxoSmithKline budgets $95M to launch a 'living genome' drug research institute. Article

> Synergy soars on stellar constipation data, rekindling buyout chatter. News

Biotech Research News

> New tool for brown fat drug development research. Item

> Harvard team transplants circadian wiring, pointing to new drug applications. More

> Scripps spotlights PPARy inhibitor as a potential drug for bone loss. Article

> Preclinical trials show ALK1 inhibitor dalantercept may prevent metastasis. Story

> New study will test feds' support for anti-aging drug research. Report

Diagnostics News

> Welch Allyn sells out to Hill-Rom for $2.05B. Item

> OraSure to receive up to $10M from feds to develop rapid Ebola test. More

> Ariosa Diagnostics scores CE mark for prenatal test software. News

> Sequenom slapped down in prenatal testing patent battle with Ariosa. Story

> Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. Article

Pharma Marketing News

> Taking the guesswork out of sales, predictive analytics could lead way to improved pharma rep decisions. Article

> Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use. Report

> Good news for drug reps: Pay is growing again. Bad? Biotech outclasses pharma by 36%. More

> Ready to prescribe PCSK9 meds? Doctors say yes, yes, yes. Story

> Shire's Vyvanse could bag another lucrative new market in menopausal women. Article

And Finally... The FDA rolled out tough restrictions on trans fats, saying they're no longer presumed safe for humans. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.